Workflow
Specialty Food Ingredients
icon
Search documents
Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2025 Financial Results on February 20, 2026
Globenewswire· 2026-02-06 12:00
Core Viewpoint - Balchem Corporation will hold a conference call on February 20, 2026, to discuss its fourth quarter and full year 2025 results [1][2]. Group 1: Conference Call Details - The conference call is scheduled for 11:00 AM Eastern Time (ET) on February 20, 2026, hosted by Ted Harris (Chairman, President, and CEO) and Martin Bengtsson (CFO) [1]. - Fourth quarter and full year 2025 results will be published before the market opens on the same day [2]. - Institutional investors and analysts can join the call by dialing specific numbers, and the public can listen via a live webcast [3]. Group 2: Company Overview - Balchem Corporation develops, manufactures, and markets specialty ingredients aimed at enhancing health and well-being across various industries [4]. - The company operates through three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [4]. - The Human Nutrition & Health segment focuses on customized food and beverage ingredient systems, while the Animal Nutrition & Health segment supplies products for animal health markets [4].
Corbion unveils BRIGHT 2030 strategy to lead in sustainable specialty food-ingredients; outlining its strategic path and medium-term financial targets
Globenewswire· 2025-11-20 06:00
Core Insights - Corbion is holding its Capital Markets Day to present its new strategy, BRIGHT 2030, aimed at leading in sustainable specialty food ingredients for preservation and nutrition [1][3] Strategic Priorities - The company aims to accelerate clean-label preservation and formulation in food to meet rising consumer demand for transparency and natural solutions [5] - Corbion plans to expand algal fermentation beyond omega-3 oils, creating new opportunities in both pet food and human nutrition [5] - Growth in Biomedical Polymers is a focus, reinforcing Corbion's presence in high-value healthcare applications [5] - A strategic ownership review of the PLA portfolio has been initiated [5] Financial Objectives (2026-2028) - The company targets organic sales growth of 3-6% per annum [5] - An adjusted EBITDA margin of approximately 18% is expected by 2028 [5] - Cumulative free cash flow is projected to reach €270 million over the period from 2026 to 2028 [5]